Stock Events

Stock Events

Prostatype Genomics AB 

$0.008800
2
+$0.00+0%Wednesday 13:30

Statistics

Day High
0.3584
Day Low
0.3584
52W High
0.3584
52W Low
0.0088
Volume
350
Avg. Volume
100
Mkt Cap
520,863.2
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-7,470.58%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
63,774.26Revenue
-4.76MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Myriad Genetics
MYGN
Mkt Cap607.38M
Myriad Genetics provides molecular diagnostic products that include prognostic medicine for prostate cancer, directly competing with Prostatype Genomics' offerings.
Illumina
ILMN
Mkt Cap35.63B
Illumina manufactures sequencing systems that are used in cancer genomics, impacting the broader market including prostate cancer diagnostics.
Fulgent Genetics
FLGT
Mkt Cap567.37M
Fulgent Genetics offers comprehensive genetic testing, including for cancer, which places them in direct competition with Prostatype Genomics in the genomic profiling market.
Pacific Biosciences of California
PACB
Mkt Cap809.71M
Pacific Biosciences offers sequencing technologies that are used in genomic research, including cancer, indirectly competing with Prostatype Genomics.
Qiagen NV
QGEN
Mkt Cap10.37B
Qiagen provides sample to insight solutions including for cancer, with technologies that compete in the genomic diagnostics market.
Quest Diagnostics
DGX
Mkt Cap27.79B
Quest Diagnostics offers diagnostic testing, including for cancers such as prostate cancer, competing with Prostatype Genomics in the diagnostics market.

About

Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers a Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, RTqPCR kit, patient database and algorithms, Prostatype Web System (PWS), and tumor stage, as well as calculates the P-score. Its test is based on a database containing prostate cancer patients; and provides decision support for patients and doctors when making a treatment decision. The company was incorporated in 2007 and is headquartered in Nacka Strand, Sweden.
Show More
CEO
Mr. Fredrik Rickman
Country
Sweden
ISIN
SE0023261532
WKN
000A40P4W

Listings

OTC Link
US
PGABF
ST
SE
PROGEN-BT-UN.ST
F
DE
PGO0.F
ST
SE
PROGEN.ST

0 Comments

Share your thoughts

FAQs

What is Prostatype Genomics AB stock price today?▼
The current price of PGABF is $0.01 USD — it has increased by +0% in the past 24 hours. Watch Prostatype Genomics AB stock price performance more closely on the chart.
What is Prostatype Genomics AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Prostatype Genomics AB stocks are traded under the ticker PGABF.
What is Prostatype Genomics AB market cap?▼
Today Prostatype Genomics AB has the market capitalization of 520,863.2
What is Prostatype Genomics AB revenue for the last year?▼
Prostatype Genomics AB revenue for the last year amounts to 63,774.26 USD.
What is Prostatype Genomics AB net income for the last year?▼
PGABF net income for the last year is -4.76M USD.
In which sector is Prostatype Genomics AB located?▼
Prostatype Genomics AB operates in the Other sector.
When did Prostatype Genomics AB complete a stock split?▼
Prostatype Genomics AB has not had any recent stock splits.
Where is Prostatype Genomics AB headquartered?▼
Prostatype Genomics AB is headquartered in Solna, Sweden.